Search results for " Liver Disease"

showing 10 items of 559 documents

Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.

2021

[Background & Aims] Non-invasive scoring systems (NSS) are used to identify patients with non-alcoholic fatty liver disease (NAFLD) who are at risk of advanced fibrosis, but their reliability in predicting long-term outcomes for hepatic/extrahepatic complications or death and their concordance in cross-sectional and longitudinal risk stratification remain uncertain.

0301 basic medicineAdultMalemedicine.medical_specialtyCirrhosisConcordanceSettore MED/12 - GASTROENTEROLOGIAHFSDiseaseBARDGastroenterologySeverity of Illness IndexTime03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseasePredictive Value of TestsInternal medicineNFSmedicineHumansIn patientAPRINSSHepatologybusiness.industryFatty liverNASHReproducibility of ResultsMiddle Agedmedicine.diseasePrognosisAPRI BARD FIB-4 HFS NASH NFS NSS Adult Area Under Curve Cross-Sectional Studies Female Humans Liver MaleMiddle Aged Non-alcoholic Fatty Liver DiseasePrognosis ROC CurveReproducibility of Results Research Design Severity of Illness Index Predictive Value of Tests Time030104 developmental biologyCross-Sectional StudiesLiverROC CurveResearch DesignArea Under CurveCohortAPRI; BARD; FIB-4; HFS; NASH; NFS; NSSFIB-4030211 gastroenterology & hepatologyFemalebusinessLiver cancerJournal of hepatology
researchProduct

Liver Fat Content in People with Pituitary Diseases: Influence of Serum IGF1 Levels

2017

AbstractNon-alcoholic fatty liver disease (NAFLD) is commonly associated with obesity, metabolic syndrome, and type 2 diabetes. NAFLD is also seen in patients with endocrinopathies. However, the relationship between endocrine diseases and the development of NAFLD is not well known. In this study, we set out to determine whether liver fat content (LFC) was associated with IGF1 levels in people with pituitary diseases (PD). Eighty-nine patients with pituitary diseases and 74 healthy controls were included in this study. LFC was measured using MRI. Hepatic steatosis was defined as LFC>5.5%. Patients with PD were older, and had a higher BMI than healthy controls. LFC was significantly higher…

0301 basic medicineAdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical Biochemistry030209 endocrinology & metabolismDiseaseType 2 diabetesIntra-Abdominal FatBiochemistryBody Mass Index03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyLiver fatmedicinesteatosisEndocrine systemHumansProspective StudiesInsulin-Like Growth Factor Ibusiness.industryBiochemistry (medical)Fatty liverIGF1pituitary diseasesnon-alcoholic fatty liver diseaseGeneral MedicineMiddle Agedmedicine.diseaseObesity030104 developmental biologyEndocrinologyCase-Control StudiesFemaleSteatosisMetabolic syndromebusinessBiomarkers
researchProduct

Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV-monoinfected patients

2020

Objectives: Current guidelines recommend use of a diagnostic algorithm to assess disease severity in cases of suspected nonalcoholic fatty liver disease (NAFLD). We applied this algorithm to HIV-monoinfected patients. Methods: We analysed three prospective screening programmes for NAFLD carried out in the following cohorts: the Liver Disease in HIV (LIVEHIV) cohort in Montreal, the Modena HIV Metabolic Clinic (MHMC) cohort and the Liver Pathologies in HIV in Palermo (LHivPa) cohort. In the LIVEHIV and LHivPa cohorts, NAFLD was diagnosed if the controlled attenuation parameter (CAP) was ≥ 248 dB/m; in the MHMC cohort, it was diagnosed if the liver/spleen Hounsfield unit (HU) ratio on abdomin…

0301 basic medicineAdultMalenonalcoholic fatty liver diseasemedicine.medical_specialtyCanadaHIV monoinfection; fibrosis-4; guidelines; nonalcoholic fatty liver disease; specialist referralHIV monoinfectionHIV InfectionsSeverity of Illness Index03 medical and health sciencesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicineDiabetes mellitusNonalcoholic fatty liver diseasespecialist referralmedicineHumansPharmacology (medical)030212 general & internal medicineProspective Studiesbusiness.industryHealth Policyfibrosis-4Alanine TransaminaseHepatologyMiddle Agedmedicine.disease030112 virologyObesityInfectious DiseasesItalyCohortPractice Guidelines as TopicCoinfectionFemaleGuideline AdherencebusinessViral hepatitisTomography X-Ray ComputedguidelineAlgorithms
researchProduct

The endocannabinoid-alcohol crosstalk: Recent advances on a bi-faceted target

2018

Increasing evidence has focusesed on the endocannabinoid system as a relevant player in the induction of aberrant synaptic plasticity and related addictive phenotype following chronic excessive alcohol drinking. In addition, the endocannabinoid system is implicated in the pathogenesis of alcoholic liver disease. Interestingly, whereas the involvement of CB1 receptors in alcohol rewarding properties is established, the central and peripheral action of CB2 signalling is still to be elucidated. This review aims at giving the input to deepen knowledge on the role of the endocannabinoid system, highlighting the advancing evidence that suggests that CB1 and CB2 receptors may play opposite roles i…

0301 basic medicineAlcoholic liver diseaseCannabinoid receptorSettore BIO/14 - FARMACOLOGIAPhysiologybrain12Inflammationliver03 medical and health sciences0302 clinical medicinePhysiology (medical)Cannabinoid receptor type 2MedicineCB; 2CB; 1endocannabinoidsReceptorPharmacologybusiness.industryalcoholmusculoskeletal neural and ocular physiologyendocannabinoidmedicine.diseaseEndocannabinoid systemCBCrosstalk (biology)030104 developmental biologynervous systemSynaptic plasticitylipids (amino acids peptides and proteins)medicine.symptombusinessNeurosciencepsychological phenomena and processes030217 neurology & neurosurgery
researchProduct

ALCOHOLIC LIVER DISEASE: A MOUSE MODEL REVEALS PROTECTION BY LACTOBACILLUS FERMENTUM

2016

Objectives Alcoholism is one of the most devastating diseases with high incidence, but knowledge of its pathology and treatment is still plagued with gaps mostly because of the inherent limitations of research with patients. We developed an animal model for studying liver histopathology, Hsp (heat-shock protein)-chaperones involvement, and response to treatment. Methods The system was standardized using mice to which ethanol was orally administered alone or in combination with Lactobacillus fermentum following a precise schedule over time and applying, at predetermined intervals, a battery of techniques (histology, immunohistochemistry, western blotting, real-time PCR, immunoprecipitation, …

0301 basic medicineAlcoholic liver diseasePathologymedicine.medical_specialtyLactobacillus fermentumOriginal ContributionsPharmacologylaw.invention03 medical and health sciencesProbioticLiver diseaselawFibrosismedicineSettore BIO/06 - Anatomia Comparata E Citologiaprobiotics lactobacillus fermentum alcoholic liver diesease HspSettore MED/12 - Gastroenterologiabiologybusiness.industryGastroenterologymedicine.diseasebiology.organism_classificationNitric oxide synthase030104 developmental biologybiology.proteinImmunohistochemistrySteatosisbusiness
researchProduct

Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease

2021

Background: The Baveno VI consensus proposed a dual liver stiffness (LS) by transient elastography threshold of <10 and >15 kPa for excluding and diagnosing compensated advanced chronic liver disease (cACLD) in the absence of other clinical signs. Herein, we aimed to validate these criteria in a real-world multicentre study. Methods: We included 5,648 patients (mean age 51 ± 13 years, 53% males) from 10 European liver centres who had a liver biopsy and LS measurement within 6 months. We included patients with chronic hepatitis C (n = 2,913, 52%), non-alcoholic fatty liver disease (NAFLD, n = 1,073, 19%), alcohol-related liver disease (ALD, n = 946, 17%) or chronic hepatitis B (n = 716…

0301 basic medicineAlcoholic liver diseasemedicine.medical_specialtyCirrhosis[SDV]Life Sciences [q-bio]Chronic liver diseaseAsymptomaticGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineInternal medicineNAFLDmedicineViral hepatitis10. No inequalityPortal hypertensionComputingMilieux_MISCELLANEOUSCirrhosiHepatologymedicine.diagnostic_testbusiness.industryFatty liverAlcoholic liver diseasemedicine.disease3. Good health030104 developmental biologyFibroscanCirrhosisLiver biopsyFIB-4030211 gastroenterology & hepatologymedicine.symptomTransient elastographybusinessViral hepatitis.
researchProduct

A two gene-based risk score predicts alcoholic cirrhosis development in males with at-risk alcohol consumption

2019

Rosellina Margherita Mancina,1,* Flaminia Ferri,2,* Alessio Farcomeni,3 Antonio Molinaro,1 Angela Maffongelli,4 Monica Mischitelli,2 Edoardo Poli,2 Lucia Parlati,5 Maria Antonella Burza,6 Adriano De Santis,2 Fabio Attilia,2 Claudia Rotondo,2 Maria Margherita Rando,2 Maria Luisa Attilia,2 Mauro Ceccanti,2 Stefano Ginanni Corradini2 1Department of Molecular and Clinical Medicine, The Sahlgrenska Academy at the University of Gothenburg, Wallenberg Laboratory, Göteborg, Sweden; 2Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; 3Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy; 4Department of Gener…

0301 basic medicineAlcoholic liver diseasemedicine.medical_specialtylcsh:QH426-470AlcoholGastroenterologyPredictive score03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineGeneticsAllelePNPLA3Genetics (clinical)Original Researchlcsh:R5-920Framingham Risk ScoreReceiver operating characteristicbusiness.industryIncidence (epidemiology)Alcoholic cirrhosis; CD14; PNPLA3; Predictive score; Genetics; Genetics (clinical)medicine.diseaselcsh:Genetics030104 developmental biologyAlcoholic cirrhosischemistryThe Application of Clinical Geneticsbusinesslcsh:Medicine (General)Settore SECS-S/01 - StatisticaCD14Body mass index030217 neurology & neurosurgeryTM6SF2The Application of Clinical Genetics
researchProduct

Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.

2015

Background & Aims The pathogenesis and progression of non-alcoholic fatty liver disease (NAFLD) is still incompletely understood. Several nuclear receptors play a role in liver lipid metabolism and can promote hepatosteatosis, but the possible role of vitamin D receptor (VDR) in NAFLD has not been investigated. Methods The expression of liver VDR was investigated in apolipoprotein E knockout ( apoE −/− ) mice on a high fat diet, in wild-type mice on methionine and choline deficient diet and in NAFLD patients with hepatosteatosis and non-alcoholic steatohepatitis. The relevance of VDR was assessed in apoE −/− mice by deletion of VDR or paricalcitol treatment and in human HepG2 cells by VDR t…

0301 basic medicineApolipoprotein Emedicine.medical_specialtyCD36Retinoid X receptorDiet High-FatCalcitriol receptor03 medical and health sciencesMiceNon-alcoholic Fatty Liver DiseaseInternal medicinemedicineAnimalsHumansHepatologybiologyFatty liverLipid metabolismmedicine.diseaseLipid MetabolismMice Inbred C57BLDisease Models Animal030104 developmental biologyEndocrinologyLiverbiology.proteinHepatocytesReceptors Calcitriollipids (amino acids peptides and proteins)SteatosisSteatohepatitisJournal of hepatology
researchProduct

LipidMS: An R Package for Lipid Annotation in Untargeted Liquid Chromatography-Data Independent Acquisition-Mass Spectrometry Lipidomics.

2018

High resolution LC-MS untargeted lipidomics using data independent acquisition (DIA) has the potential to increase lipidome coverage, as it enables the continuous and unbiased acquisition of all eluting ions. However, the loss of the link between the precursor and the product ions combined with the high dimensionality of DIA data sets hinder accurate feature annotation. Here, we present LipidMS, an R package aimed to confidently identify lipid species in untargeted LC-DIA-MS. To this end, LipidMS combines a coelution score, which links precursor and fragment ions with fragmentation and intensity rules. Depending on the MS evidence reached by the identification function survey, LipidMS provi…

0301 basic medicineChromatographyChemistry010401 analytical chemistryLipidomeMass spectrometry01 natural sciencesLipids0104 chemical sciencesAnalytical Chemistry03 medical and health sciencesR packageAnnotation030104 developmental biologyNon-alcoholic Fatty Liver DiseaseTandem Mass SpectrometryLipidomicsLipidomicsHumansData-independent acquisitionHigh dimensionalityData dependentBiomarkersDatabases ChemicalChromatography LiquidAnalytical chemistry
researchProduct

Copper/MYC/CTR1 interplay: A dangerous relationship in hepatocellular carcinoma

2018

Free serum copper correlates with tumor incidence and progression of human cancers, including hepatocellular carcinoma (HCC). Copper extracellular uptake is provided by the transporter CTR1, whose expression is regulated to avoid excessive intracellular copper entry. Inadequate copper serum concentration is involved in the pathogenesis of Non Alcoholic Fatty Liver Disease (NAFLD), which is becoming a major cause of liver damage progression and HCC incidence. Finally, MYC is over-expressed in most of HCCs and is a critical regulator of cellular growth, tumor invasion and metastasis. The purpose of our study was to understand if higher serum copper concentrations might be involved in the prog…

0301 basic medicineCirrhosisCopper; CTR1; Hepatocellular carcinoma; MYC; Non alcoholic fatty liver disease; OncologyMYCMetastasis03 medical and health sciencesmedicineOncogeneCell growthChemistryFatty liverCTR1hepatocellular carcinomaHCCSmedicine.diseasedigestive system diseases3. Good health030104 developmental biologyOncologyHepatocellular carcinomacopperCancer researchCTR1; MYC; copper; hepatocellular carcinoma; non alcoholic fatty liver diseaseLiver cancerResearch Papernon alcoholic fatty liver disease
researchProduct